Correlation Between Vitamin D and Symptoms Severity of Autonomic Nervous Mediated Syncope Child and it 's RAAS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-20

Study Completion Date

2022-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

children ; autonomic nervous mediated syncope； vitamin D ; symptom score ; renin-angiotensin-aldosterone-system

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome

NCT01265589

RDS Infant, Newborn Vitamin A +1 more

UNKNOWN PHASE3

The Effect of Melatonin on Nocturnal Enuresis

NCT01575678

Nocturnal Enuresis

UNKNOWN PHASE2

Effects of Fat-soluble Vitamins Supplementation on Common Complications and Neural Development in Very Low Birth Weight Infants

NCT03876704

Vitamin A Deficiency Vitamin D Deficiency Vitamin E Deficiency +4 more

UNKNOWN PHASE3

Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker

NCT06489951

Overactive Bladder Pediatric Disorder

COMPLETED NA

Liq-NOL Efficacy in Pediatric Patients With Down Syndrome

NCT00891917

Down Syndrome

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

children with autonomic nervous mediated syncope have seriously affects children's physical and mental health and quality of life, and the incidence rate is also increasing year by year. But the current treatment measures are not ideal, Therefore, we need to look for new biological indicators, according to different biological indicators to develop different treatment options, so as to improve the current situation of poor treatment of children with NMS

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitamin D

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clinical Study of Vitamin D in Children With NMS

Correlation between vitamin D and symptoms severity of autonomic nervous mediated syncope child and it 's RAAS

Group Type OTHER

Vitamin D

Intervention Type DRUG

Clinical Study

Full automatic chemiluminescence measuring instrument

Intervention Type DEVICE

Chemiluminescence immunoassay

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D

Clinical Study

Intervention Type DRUG

Full automatic chemiluminescence measuring instrument

Chemiluminescence immunoassay

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vitamin D drops

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children diagnosed with OI;
* Compliance with the diagnostic guidelines for Syncope in children (2016 edition) and 2018 syncope in children and adolescents in the cardiovascular group of the Society of Pediatrics, Chinese Medical Association The diagnostic criteria of Oi in the Diagnostic and therapeutic guidelines.

Exclusion Criteria

* Taken 3 months prior to admission Vitamin D or hormone drugs;
* Heart, brain, nerves, metabolism, blood and other apparatus Syncope or aura of syncope caused by a qualitative disease;

Minimum Eligible Age

5 Years

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes